Website
News25/Ratings12
News · 26 weeks69-71%
2025-10-262026-04-19
Mix5290d
- Insider32(62%)
- SEC Filings8(15%)
- Other7(13%)
- Earnings3(6%)
- Analyst1(2%)
- Dividends1(2%)
Latest news
25 items- SECSEC Form 10-Q filed by Quest Diagnostics Incorporated10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- SECQuest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRQuest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.
- PRCity of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple CancersFourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancerSECAUCUS, N.J. and LOS ANGELES, April 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, is implementing Haystack MRD®, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast,
- SECSEC Form DEFA14A filed by Quest Diagnostics IncorporatedDEFA14A - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- SECSEC Form DEF 14A filed by Quest Diagnostics IncorporatedDEF 14A - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- INSIDERSEC Form 4 filed by Wentworth Timothy C4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quest Diagnostics IncorporatedSCHEDULE 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
- PRQuest Diagnostics to Release First Quarter Financial Results on April 21, 2026SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on w
- SECQuest Diagnostics Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRQuest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of DirectorsSECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members. "As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics. "His depth in the many chan
- INSIDERSEC Form 3 filed by Quest Diagnostics Incorporated3 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSEC Form 4 filed by Quest Diagnostics Incorporated4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERExecutive Vice President & CFO Samad Sam was granted 13,947 shares and covered exercise/tax liability with 7,720 shares, increasing direct ownership by 23% to 33,268 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDEREVP, Regional Businesses Doherty Catherine T. was granted 11,364 shares, covered exercise/tax liability with 5,806 shares and sold $1,146,115 worth of shares (5,558 units at $206.21) (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & General Counsel Prevoznik Michael E was granted 7,232 shares, covered exercise/tax liability with 3,354 shares and sold $799,682 worth of shares (3,878 units at $206.21) (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & Chief Commercial Officer Delaney Mark E was granted 5,682 shares and covered exercise/tax liability with 2,326 shares, increasing direct ownership by 39% to 11,864 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERCEO and President Davis J. E. was granted 51,652 shares and covered exercise/tax liability with 26,414 shares, increasing direct ownership by 22% to 142,423 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP for Diagnostic Services Plewman Patrick sold $588,730 worth of shares (2,855 units at $206.21), was granted 5,682 shares and covered exercise/tax liability with 2,827 shares (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP, Corp. Controller & CAO Deppe Michael J was granted 1,473 shares and covered exercise/tax liability with 750 shares, increasing direct ownership by 2% to 35,196 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP, Clinical Solutions Kuppusamy Karthik was granted 6,200 shares and sold $538,372 worth of shares (2,628 units at $204.86), increasing direct ownership by 36% to 13,441 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDEREVP, Regional Businesses Doherty Catherine T. covered exercise/tax liability with 648 shares and sold $131,285 worth of shares (632 units at $207.73), decreasing direct ownership by 2% to 67,122 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERExecutive Vice President & CFO Samad Sam covered exercise/tax liability with 869 shares, decreasing direct ownership by 3% to 27,041 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & General Counsel Prevoznik Michael E covered exercise/tax liability with 288 shares and sold $109,266 worth of shares (526 units at $207.73), decreasing direct ownership by 2% to 37,557 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERCEO and President Davis J. E. covered exercise/tax liability with 2,968 shares and sold $2,125,200 worth of shares (10,000 units at $212.52), decreasing direct ownership by 10% to 117,185 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)